(Sharecast News) - Shares in Nanexa more than doubled on Friday after the loss-making Swedish start-up signed deal worth more than €1bn with Novo Nordisk.


The Novo Nordisk, the manufacturer of Ozempic and Wegovy, has signed an exclusive licence to use Nanexa's proprietary drug delivery technology PharmaShell platform...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE